AI-driven peptide design is revolutionizing the development of novel therapeutics. Professor Peter ‘t Hart and his team at the University of Münster leverage generative AI and wet-lab screening to identify peptides targeting RNA-binding proteins, overcoming traditional design limitations. This integrated approach accelerates discovery of innovative molecules with therapeutic potential across indications including cell and gene therapy, CRISPR, and mRNA therapeutics. Despite challenges such as sustainability and synthesis throughput, AI is reshaping the peptide therapeutics workflow and expanding drug design horizons.